JAN ANDREAS BURGER

TitleAssociate Professor
InstitutionMD Anderson
DepartmentLeukemia
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 Apr 20; 1-10. PMID: 35442137.
      Citations:    Fields:    
    2. Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia. Blood Adv. 2022 Apr 04. PMID: 35377947.
      Citations:    Fields:    
    3. Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 Apr; 63(4):885-893. PMID: 35225133.
      Citations:    Fields:    Translation:Humans
    4. Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia. 2022 05; 36(5):1324-1335. PMID: 35149845.
      Citations:    Fields:    
    5. Mazzarello AN, Gentner-Göbel E, Dühren-von Minden M, Tarasenko TN, Nicolò A, Ferrer G, Vergani S, Liu Y, Bagnara D, Rai KR, Burger JA, McGuire PJ, Maity PC, Jumaa H, Chiorazzi N. B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. J Clin Invest. 2022 01 18; 132(2). PMID: 34813501.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    6. Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 Jan 11; 1-12. PMID: 35014928.
      Citations:    Fields:    
    7. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 03; 196(5):1209-1218. PMID: 34915592.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592. PMID: 34521099.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    9. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722. PMID: 34625713.
      Citations: 1     Fields:    Translation:Humans
    10. Burger JA. CLL cells are moved by the MARCKS brothers. Blood. 2021 08 19; 138(7):503-504. PMID: 34410355.
      Citations:    Fields:    Translation:Humans
    11. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219. PMID: 34110383.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    12. Burger JA. Integrating New Therapies for Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01; 27(4):275-285. PMID: 34398554.
      Citations: 1     Fields:    Translation:Humans
    13. Smith CIE, Burger JA. Resistance Mutations to BTK Inhibitors Originate From the NF-?B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol. 2021; 12:689472. PMID: 34177947.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    14. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924. PMID: 33901324.
      Citations: 3     Fields:    Translation:Humans
    15. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429. PMID: 34007049.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    16. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 07; 194(1):61-68. PMID: 33973230.
      Citations:    Fields:    Translation:Humans
    17. Ferrer G, Jung B, Chiu PY, Aslam R, Palacios F, Mazzarello AN, Vergani S, Bagnara D, Chen SS, Yancopoulos S, Xochelli A, Yan XJ, Burger JA, Barrientos JC, Kolitz JE, Allen SL, Stamatopoulos K, Rai KR, Sherry B, Chiorazzi N. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021 11; 35(11):3163-3175. PMID: 33935280.
      Citations: 5     Fields:    Translation:HumansCells
    18. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883. PMID: 33792630.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    19. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038. PMID: 33740268.
      Citations: 1     Fields:    Translation:HumansCells
    20. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021 03 13; 11(3):57. PMID: 33714981.
      Citations: 2     Fields:    Translation:HumansCells
    21. Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8. PMID: 33689703.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    22. Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 03; 102:106520. PMID: 33611131.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    23. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620. PMID: 33087831.
      Citations: 3     Fields:    Translation:Humans
    24. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736. PMID: 32896301.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    25. Liu W, Burger JA, Xu J, Tang Z, Toruner G, Khanlari M, Medeiros LJ, Tang G. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Ann Hematol. 2020 Oct; 99(10):2343-2349. PMID: 32833105.
      Citations:    Fields:    Translation:Humans
    26. Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295. PMID: 32681739.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    27. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432. PMID: 32911375.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    28. Burger JA. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020 07 30; 383(5):460-473. PMID: 32726532.
      Citations: 36     Fields:    Translation:HumansCells
    29. de Castro CG, Gregianin LJ, Burger JA. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leuk Lymphoma. 2020 10; 61(10):2536-2537. PMID: 32611256.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    30. Malek AE, Gutierrez C, Mulanovich VE, Botdorf J, Chemaly RF, Shah S, McCall BM, Melancon JT, McConn KK, Borjan J, Raad II, Burger JA, Garcia-Manero G, Adachi JA. Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020044. PMID: 32670522.
      Citations: 2     
    31. Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020 Dec 15; 60(4):130-137. PMID: 32404571.
      Citations:    Fields:    Translation:HumansCells
    32. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739. PMID: 32170867.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    33. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020 08 01; 26(15):3918-3927. PMID: 32209572.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    34. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513. PMID: 31895947.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    35. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598. PMID: 31862959.
      Citations: 3     Fields:    Translation:HumansCells
    36. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959. PMID: 31537528.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    37. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 11 21; 134(21):1811-1820. PMID: 31558467.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    38. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J. 2019 Nov/Dec; 25(6):386-393. PMID: 31764119.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    39. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085. PMID: 31645416.
      Citations: 8     Fields:    Translation:HumansCells
    40. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798. PMID: 31628428.
      Citations: 90     Fields:    Translation:HumansCTClinical Trials
    41. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363. PMID: 31512258.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    42. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75. PMID: 31553487.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    43. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565. PMID: 31502383.
      Citations: 5     Fields:    Translation:Humans
    44. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168. PMID: 31413095.
      Citations: 1     Fields:    Translation:Humans
    45. Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(14):3461-3469. PMID: 31352850.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    46. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4. PMID: 31344256.
      Citations: 2     Fields:    Translation:Humans
    47. Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 09 12; 134(11):851-859. PMID: 31340982.
      Citations: 79     Fields:    Translation:HumansCTClinical Trials
    48. Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger JA, Herzog RW, Engel P, Terhorst C. SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 09; 7(9):1485-1496. PMID: 31315913.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    49. Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(13):3341-3342. PMID: 31305193.
      Citations:    Fields:    Translation:HumansCells
    50. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807. PMID: 31196847.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    51. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539. PMID: 31076409.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    52. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020 01; 11(1):19-23. PMID: 31005650.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    53. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. PMID: 30767298.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    54. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042. PMID: 30842083.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    55. Morande PE, Sivina M, Uriepero A, Seija N, Berca C, Fresia P, Landoni AI, Di Noia JM, Burger JA, Oppezzo P. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood. 2019 05 09; 133(19):2056-2068. PMID: 30814061.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    56. Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A. Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. Br J Haematol. 2019 07; 186(1):175-180. PMID: 30739324.
      Citations: 2     Fields:    Translation:Humans
    57. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188. PMID: 30740654.
      Citations: 4     Fields:    Translation:Humans
    58. Burger JA. Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. Clin Cancer Res. 2019 04 15; 25(8):2372-2374. PMID: 30728153.
      Citations:    Fields:    Translation:Humans
    59. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109. PMID: 30709431.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    60. Boddu P, Gibbons J, Burger J, Sivina M, Thakral B, Kanagal-Shamanna R, Ferrajoli A. Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leuk Lymphoma. 2019 06; 60(6):1568-1571. PMID: 30632839.
      Citations: 1     Fields:    Translation:Humans
    61. Hamlin PA, Flinn IW, Wagner-Johnston N, Burger JA, Coffey GP, Conley PB, Michelson G, Leeds JM, Der K, Kim Y, Sabalvaro-Torres A, Birrell M, Pandey A, Curnutte JT, Patel MR. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. Am J Hematol. 2019 04; 94(4):E90-E93. PMID: 30592080.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    62. Ten Hacken E, Gounari M, Ghia P, Burger JA. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia. 2019 02; 33(2):287-298. PMID: 30555163.
      Citations: 12     Fields:    Translation:HumansCells
    63. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019. PMID: 30530801.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    64. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574. PMID: 30508305.
      Citations: 20     Fields:    Translation:Humans
    65. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol. 2019 02; 184(4):558-569. PMID: 30506764.
      Citations: 22     Fields:    Translation:Humans
    66. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019 05; 185(3):606-608. PMID: 30406944.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    67. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-d,? inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol. 2018 11; 93(11):1318-1326. PMID: 30094870.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    68. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201. PMID: 30307606.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    69. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055. PMID: 30307611.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    70. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 11; 93(11):1402-1410. PMID: 30129285.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    71. Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). PMID: 30282833.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    72. Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 04; 60(4):1000-1005. PMID: 30277101.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    73. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMID: 30319961.
      Citations: 8     
    74. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718. PMID: 30263097.
      Citations: 3     Fields:    
    75. Peled A, Klein S, Beider K, Burger JA, Abraham M. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine. 2018 09; 109:11-16. PMID: 29903571.
      Citations: 29     Fields:    Translation:Humans
    76. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141. PMID: 30028037.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    77. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421. PMID: 30115541.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    78. Burger JA, O'Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018 08; 15(8):510-527. PMID: 29777163.
      Citations: 38     Fields:    Translation:Humans
    79. O'Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):648-657.e15. PMID: 30061088.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    80. Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA. Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA). Blood Res. 2018 Jun; 53(2):169-172. PMID: 29963527.
      Citations: 1     
    81. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 09; 103(9):1502-1510. PMID: 29880603.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    82. Burger JA. New pieces in the BTKi resistance puzzle. Blood. 2018 05 03; 131(18):1995-1996. PMID: 29724714.
      Citations:    Fields:    Translation:Cells
    83. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747. PMID: 29723397.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    84. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280. PMID: 29765537.
      Citations: 17     Fields:    
    85. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398. PMID: 29769624.
      Citations: 11     Fields:    Translation:Humans
    86. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691. PMID: 29465264.
      Citations: 9     Fields:    Translation:HumansCells
    87. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. PMID: 29479067.
      Citations: 2     Fields:    Translation:Humans
    88. O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 04 26; 131(17):1910-1919. PMID: 29437592.
      Citations: 146     Fields:    Translation:HumansCTClinical Trials
    89. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832. PMID: 29358183.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    90. Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018 03; 18(3):148-167. PMID: 29348577.
      Citations: 98     Fields:    Translation:HumansCells
    91. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248. PMID: 29352703.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    92. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720. PMID: 29632735.
      Citations: 4     Fields:    
    93. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2017; 8:1773. PMID: 29379494.
      Citations: 12     Fields:    
    94. Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018 02 05; 215(2):681-697. PMID: 29301866.
      Citations: 24     Fields:    Translation:Humans
    95. Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJ. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185. PMID: 29259203.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    96. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 02 22; 131(8):877-887. PMID: 29191916.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    97. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40. PMID: 29164608.
      Citations: 11     Fields:    Translation:HumansCells
    98. Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018 01; 27(1):31-42. PMID: 29125406.
      Citations: 22     Fields:    Translation:HumansAnimals
    99. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99. PMID: 29047158.
      Citations: 20     Fields:    Translation:Humans
    100. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322. PMID: 28972430.
      Citations: 4     Fields:    Translation:Humans
    101. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901. PMID: 28927784.
      Citations: 41     Fields:    Translation:Humans
    102. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496. PMID: 28798068.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    103. Jain P, Burger JA, Khoury JD. CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol. 2017 10; 92(10):1113-1114. PMID: 28670739.
      Citations: 1     Fields:    Translation:HumansCells
    104. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081. PMID: 28722170.
      Citations: 10     Fields:    Translation:HumansCells
    105. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805. PMID: 28751558.
      Citations: 69     Fields:    Translation:Humans
    106. ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 10; 102(10):e394-e396. PMID: 28751563.
      Citations: 5     Fields:    Translation:HumansCells
    107. Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017 08 24; 130(8):995-1006. PMID: 28646116.
      Citations: 28     Fields:    Translation:HumansCells
    108. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. PMID: 28397242.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    109. Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615. PMID: 28373262.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    110. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112. PMID: 27655665.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    111. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273. PMID: 28171709.
      Citations: 40     Fields:    Translation:Humans
    112. Ten Hacken E, Burger JA. HSP90, a chaperone that can make you SYK. Blood. 2017 02 02; 129(5):542-544. PMID: 28153836.
      Citations: 1     Fields:    Translation:Humans
    113. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618. PMID: 28130399.
      Citations: 12     Fields:    Translation:HumansCells
    114. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017 01 26; 2(2):e89904. PMID: 28138560.
      Citations: 38     Fields:    Translation:Humans
    115. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74. PMID: 28089238.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    116. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747. PMID: 28077600.
      Citations: 52     Fields:    Translation:HumansCells
    117. Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC, O'Brien S. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Cancer Res. 2017 Mar 01; 23(5):1149-1155. PMID: 28073846.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    118. Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017 03 02; 129(9):1155-1165. PMID: 28031181.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    119. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11. PMID: 27673440.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    120. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600. PMID: 27766619.
      Citations: 2     Fields:    Translation:Humans
    121. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158. PMID: 27797975.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    122. Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica. 2017 02; 102(2):373-380. PMID: 27742770.
      Citations: 28     Fields:    Translation:HumansCells
    123. Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016 Oct 04; 7(40):65968-65981. PMID: 27602755.
      Citations: 42     Fields:    Translation:HumansCells
    124. Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2313-2324. PMID: 27697994.
      Citations: 23     Fields:    Translation:HumansCells
    125. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479. PMID: 27468087.
      Citations: 9     Fields:    Translation:Humans
    126. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016 09 15; 197(6):2522-31. PMID: 27534555.
      Citations: 13     Fields:    Translation:HumansCells
    127. Chihara D, Kantarjian H, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep; 174(5):760-6. PMID: 27301277.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    128. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. PMID: 27199251.
      Citations: 125     Fields:    Translation:Humans
    129. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 08 15; 122(16):2505-11. PMID: 27182988.
      Citations: 16     Fields:    Translation:Humans
    130. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. PMID: 27151992.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    131. Burger JA. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia. Clin Adv Hematol Oncol. 2016 May; 14(5 Suppl 8):7-12. PMID: 27168204.
      Citations: 1     Fields:    Translation:Humans
    132. Coutre SE, Burger JA, Pagel JM. Discussion: Managing Risk When Using Idelalisib. Clin Adv Hematol Oncol. 2016 May; 14(5 Suppl 8):13. PMID: 27168205.
      Citations: 3     Fields:    Translation:Humans
    133. Burger JA, Styles L, Kipps TJ. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5. PMID: 27096594.
      Citations: 3     Fields:    Translation:Humans
    134. Vitale C, Burger JA. Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opin Pharmacother. 2016 Jun; 17(8):1077-89. PMID: 26988407.
      Citations: 4     Fields:    Translation:Humans
    135. Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, Peled A, Davis RE, Konopleva M, Burger JA. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2016 08; 174(3):425-36. PMID: 27071778.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    136. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8. PMID: 27013651.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    137. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9. PMID: 26800008.
      Citations:    Fields:    Translation:Humans
    138. Burger JA. Obinutuzumab: the more the merrier? Blood. 2016 Jan 07; 127(1):6-8. PMID: 26744434.
      Citations:    Fields:    Translation:Humans
    139. Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res. 2016 05 15; 22(10):2359-67. PMID: 26733610.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    140. Koehrer S, Burger JA. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. 2016 Jan; 14(1):55-65. PMID: 27057669.
      Citations: 11     Fields:    Translation:HumansCells
    141. Okkenhaug K, Burger JA. Erratum to: PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:E1. PMID: 29210027.
      Citations: 1     Fields:    
    142. Okkenhaug K, Burger JA. PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol. 2016; 393:123-142. PMID: 26350103.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    143. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37. PMID: 26639149.
      Citations: 440     Fields:    Translation:HumansCTClinical Trials
    144. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. ß2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73. PMID: 26588193.
      Citations: 10     Fields:    Translation:HumansCells
    145. Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Casaus J, Castellini G, Cernuda I, Cerreta D, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen GM, Chen H, Chen HS, Cheng L, Chou HY, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Gil EC, Coste B, Creus W, Crispoltoni M, Cui Z, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Donnini F, Duranti M, D'Urso D, Egorov A, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Formato V, Galaktionov Y, Gallucci G, García B, García-López R, Gargiulo C, Gast H, Gebauer I, Gervasi M, Ghelfi A, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Haas D, Habiby M, Haino S, Han KC, He ZH, Heil M, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Korkmaz MA, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Li HL, Li JQ, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Liu H, Lolli M, Lomtadze T, Lu MJ, Lu SQ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Lv SS, Majka R, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Morescalchi L, Mott P, Müller M, Nelson T, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pauluzzi M, Pedreschi E, Pensotti S, Pereira R, Picot-Clemente N, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Putze A, Quadrani L, Qi XM, Qin X, Qu ZY, Räihä T, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Sandweiss J, Saouter P, Schael S, Schmidt SM, von Dratzig AS, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Song JW, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SC, Ting SM, Tomassetti N, Torsti J, Türkoglu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Vitale V, Vitillo S, Wang LQ, Wang NH, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Willenbrock M, Wu H, Wu X, Xia X, Xie M, Xie S, Xiong RQ, Xu NS, Xu W, Yan Q, Yang J, Yang M, Yang Y, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang C, Zhang JH, Zhang MT, Zhang SD, Zhang SW, Zhang XB, Zhang Z, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Precision Measurement of the Helium Flux in Primary Cosmic Rays of Rigidities 1.9 GV to 3 TV with the Alpha Magnetic Spectrometer on the International Space Station. Phys Rev Lett. 2015 Nov 20; 115(21):211101. PMID: 26636836.
      Citations: 16     Fields:    
    146. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400. PMID: 26492205.
      Citations: 36     Fields:    Translation:Humans
    147. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. PMID: 26472751.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    148. Hartmann EM, Rudelius M, Burger JA, Rosenwald A. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leuk Lymphoma. 2016; 57(3):563-71. PMID: 26458057.
      Citations: 14     Fields:    Translation:HumansCells
    149. Sivina M, Burger JA. The importance of the tissue microenvironment in hairy cell leukemia. Best Pract Res Clin Haematol. 2015 Dec; 28(4):208-16. PMID: 26614899.
      Citations: 3     Fields:    Translation:HumansCells
    150. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140.
      Citations: 28     Fields:    Translation:HumansCells
    151. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    152. Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904. PMID: 26217876.
      Citations: 19     Fields:    Translation:Humans
    153. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21. PMID: 26193999.
      Citations: 86     Fields:    Translation:HumansCells
    154. Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016 Mar; 1863(3):401-413. PMID: 26193078.
      Citations: 91     Fields:    Translation:HumansCells
    155. Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bigongiari G, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Casaus J, Cascioli V, Castellini G, Cernuda I, Cerreta D, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen H, Cheng GM, Chen HS, Cheng L, Chou HY, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Cortina Gil E, Coste B, Creus W, Crispoltoni M, Cui Z, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Donnini F, Du WJ, Duranti M, D'Urso D, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Galaktionov Y, Gallucci G, García B, García-López R, Gargiulo C, Gast H, Gebauer I, Gervasi M, Ghelfi A, Gillard W, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Haas D, Habiby M, Haino S, Han KC, He ZH, Heil M, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Levi G, Li HL, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Lolli M, Lomtadze T, Lu MJ, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Lv SS, Majka R, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Morescalchi L, Mott P, Müller M, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pauluzzi M, Pedreschi E, Pensotti S, Pereira R, Picot-Clemente N, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Postaci E, Putze A, Quadrani L, Qi XM, Qin X, Qu ZY, Räihä T, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Sandweiss J, Saouter P, Sbarra C, Schael S, Schmidt SM, Schulz von Dratzig A, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SC, Ting SM, Tomassetti N, Torsti J, Türkoglu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Vitale V, Vitillo S, Wang LQ, Wang NH, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Wu H, Wu X, Xia X, Xie M, Xie S, Xiong RQ, Xin GM, Xu NS, Xu W, Yan Q, Yang J, Yang M, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang JH, Zhang MT, Zhang XB, Zhang Z, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P, Zurbach C. Precision Measurement of the Proton Flux in Primary Cosmic Rays from Rigidity 1 GV to 1.8 TV with the Alpha Magnetic Spectrometer on the International Space Station. Phys Rev Lett. 2015 May 01; 114(17):171103. PMID: 25978222.
      Citations: 22     Fields:    
    156. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22. PMID: 25917267.
      Citations: 71     Fields:    Translation:HumansCells
    157. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63. PMID: 25847930.
      Citations: 11     Fields:    Translation:Humans
    158. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7. PMID: 25683856.
      Citations: 2     Fields:    Translation:HumansCells
    159. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Oct; 171(2):281-284. PMID: 25824652.
      Citations: 2     Fields:    
    160. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer. 2015 Jul 15; 121(14):2375-82. PMID: 25809968.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    161. Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian H. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015 May 21; 125(21):3236-45. PMID: 25795921.
      Citations: 62     Fields:    Translation:Humans
    162. Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015 May 07; 125(19):2915-22. PMID: 25755291.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    163. Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH, Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 09; 27(3):409-25. PMID: 25759025.
      Citations: 58     Fields:    Translation:HumansCells
    164. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53. PMID: 25733697.
      Citations: 34     Fields:    Translation:Humans
    165. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14. PMID: 25724525.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    166. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):385-91. PMID: 25817936.
      Citations: 4     Fields:    Translation:Humans
    167. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015 Apr 16; 125(16):2497-506. PMID: 25700432.
      Citations: 251     Fields:    Translation:Humans
    168. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7. PMID: 25573991.
      Citations: 121     Fields:    Translation:Humans
    169. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2015 Jul; 170(1):125-8. PMID: 25522014.
      Citations: 7     Fields:    Translation:HumansCells
    170. Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46. PMID: 25499217.
      Citations: 20     Fields:    Translation:HumansCells
    171. Badar T, Burger JA, Wierda WG, O'Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol. 2014 Dec; 7(6):705-17. PMID: 25387837.
      Citations: 4     Fields:    Translation:HumansCells
    172. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015 Jun; 56(6):1643-50. PMID: 25308294.
      Citations: 36     Fields:    Translation:Humans
    173. Accardo L, Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bigongiari G, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Carosi G, Casaus J, Cascioli V, Castellini G, Cernuda I, Cerreta D, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen H, Cheng GM, Chen HS, Cheng L, Chikanian A, Chou HY, Choumilov E, Choutko V, Chung CH, Cindolo F, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Coste B, Cui Z, Dai M, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Du WJ, Duranti M, D'Urso D, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Galaktionov Y, Gallucci G, García B, García-López R, Gast H, Gebauer I, Gervasi M, Ghelfi A, Gillard W, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Haas D, Habiby M, Haino S, Han KC, He ZH, Heil M, Henning R, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, Kunz S, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Levi G, Li HL, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Lolli M, Lomtadze T, Lu MJ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Lv SS, Majka R, Malinin A, Mañá C, Marín J, Martin T, Martínez G, Masi N, Massera F, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Monreal B, Morescalchi L, Mott P, Müller M, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pauluzzi M, Pedreschi E, Pensotti S, Pereira R, Pilastrini R, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Postaci E, Putze A, Quadrani L, Qi XM, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rossi L, Rozhkov A, Rozza D, Rybka G, Sagdeev R, Sandweiss J, Saouter P, Sbarra C, Schael S, Schmidt SM, Schuckardt D, Schulz von Dratzig A, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SC, Ting SM, Tomassetti N, Torsti J, Türkoglu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Vitale V, Volpini G, Wang LQ, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Wu H, Wu KY, Xia X, Xie M, Xie S, Xiong RQ, Xin GM, Xu NS, Xu W, Yan Q, Yang J, Yang M, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang JH, Zhang MT, Zhang XB, Zhang Z, Zheng ZM, Zhou F, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P, Zurbach C. High statistics measurement of the positron fraction in primary cosmic rays of 0.5-500 GeV with the alpha magnetic spectrometer on the international space station. Phys Rev Lett. 2014 Sep 19; 113(12):121101. PMID: 25279616.
      Citations: 8     Fields:    
    174. Aguilar M, Aisa D, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bigongiari G, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Casaus J, Cascioli V, Castellini G, Cernuda I, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen H, Cheng GM, Chen HS, Cheng L, Chikanian A, Chou HY, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Coste B, Cui Z, Dai M, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Du WJ, Duranti M, D'Urso D, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Galaktionov Y, Gallucci G, García B, García-López R, Gast H, Gebauer I, Gervasi M, Ghelfi A, Gillard W, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Habiby M, Haino S, Han KC, He ZH, Heil M, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, Kunz S, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Li HL, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Lomtadze T, Lu MJ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Lv SS, Majka R, Malinin A, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Morescalchi L, Mott P, Müller M, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pedreschi E, Pensotti S, Pereira R, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Postaci E, Putze A, Quadrani L, Qi XM, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Sandweiss J, Saouter P, Sbarra C, Schael S, Schmidt SM, Schuckardt D, Schulz von Dratzig A, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SC, Ting SM, Tomassetti N, Torsti J, Türkoglu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Wang LQ, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Wu H, Xia X, Xie M, Xie S, Xiong RQ, Xin GM, Xu NS, Xu W, Yan Q, Yang J, Yang M, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang JH, Zhang MT, Zhang XB, Zhang Z, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P, Zurbach C. Electron and positron fluxes in primary cosmic rays measured with the alpha magnetic spectrometer on the international space station. Phys Rev Lett. 2014 Sep 19; 113(12):121102. PMID: 25279617.
      Citations: 10     Fields:    
    175. Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2014 Sep 23; 111(38):13906-11. PMID: 25201956.
      Citations: 39     Fields:    Translation:Humans
    176. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9. PMID: 25150798.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    177. ten Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. 2014 Dec; 144(3):338-48. PMID: 25050922.
      Citations: 21     Fields:    Translation:HumansCells
    178. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501. PMID: 25043749.
      Citations: 3     Fields:    Translation:Humans
    179. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug; 99(8):1350-5. PMID: 24859876.
      Citations: 27     Fields:    Translation:HumansCells
    180. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-activated GM-CSFRa translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res. 2014 Sep; 12(9):1267-82. PMID: 24836891.
      Citations: 10     Fields:    Translation:HumansCells
    181. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26; 123(26):4132-5. PMID: 24829205.
      Citations: 39     Fields:    Translation:HumansCellsCTClinical Trials
    182. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802. PMID: 24778152.
      Citations: 37     Fields:    Translation:HumansCells
    183. Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014 Jun 10; 32(17):1830-9. PMID: 24778403.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    184. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32. PMID: 24705492.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    185. Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014 Jul; 166(2):177-88. PMID: 24697238.
      Citations: 21     Fields:    Translation:HumansCells
    186. Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kd in patients with B-cell malignancies. Nat Rev Clin Oncol. 2014 Apr; 11(4):184-6. PMID: 24642682.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    187. Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar; 9(1):44-9. PMID: 24357428.
      Citations: 39     Fields:    Translation:Humans
    188. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7. PMID: 24779033.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    189. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    190. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014 Mar 20; 32(9):897-904. PMID: 24516016.
      Citations: 64     Fields:    Translation:Humans
    191. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12):e83830. PMID: 24376763.
      Citations: 43     Fields:    Translation:AnimalsCells
    192. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8. PMID: 24440659.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    193. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan; 15(1):48-58. PMID: 24332241.
      Citations: 176     Fields:    Translation:HumansCTClinical Trials
    194. ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res. 2014 Feb 01; 20(3):548-56. PMID: 24323900.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    195. Burger JA, Liberov B, Yurd F, Loffeld RJ. A Case of Extreme Gastroparesis due to an Occult Small Cell Cancer of the Lung. Case Rep Gastrointest Med. 2013; 2013:182962. PMID: 24368948.
      Citations: 1     
    196. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 2014 Feb 13; 123(7):1032-9. PMID: 24277076.
      Citations: 80     Fields:    Translation:HumansCells
    197. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30. PMID: 24355079.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    198. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5. PMID: 24157581.
      Citations: 18     Fields:    Translation:Humans
    199. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9. PMID: 24060289.
      Citations: 4     Fields:    Translation:Humans
    200. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9. PMID: 23913852.
      Citations: 28     Fields:    Translation:Humans
    201. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014 Feb; 24:71-81. PMID: 24018164.
      Citations: 128     Fields:    Translation:HumansCells
    202. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013 Nov; 54(11):2385-91. PMID: 23425038.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    203. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer. 2013 Nov 01; 119(21):3805-11. PMID: 23943357.
      Citations: 16     Fields:    Translation:Humans
    204. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013 Dec; 34(12):592-601. PMID: 23928062.
      Citations: 120     Fields:    Translation:HumansAnimalsCells
    205. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561.
      Citations: 76     Fields:    Translation:HumansCells
    206. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 04; 369(1):32-42. PMID: 23782158.
      Citations: 820     Fields:    Translation:HumansCTClinical Trials
    207. Burger JA. Osteopontin: an unhealthy sleep remedy for ALL. Blood. 2013 Jun 13; 121(24):4814-5. PMID: 23766457.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    208. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013 Jun 01; 12:50. PMID: 23725032.
      Citations: 37     Fields:    Translation:HumansCells
    209. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62. PMID: 23613521.
      Citations: 155     Fields:    Translation:HumansCellsCTClinical Trials
    210. Aguilar M, Alberti G, Alpat B, Alvino A, Ambrosi G, Andeen K, Anderhub H, Arruda L, Azzarello P, Bachlechner A, Barao F, Baret B, Barrau A, Barrin L, Bartoloni A, Basara L, Basili A, Batalha L, Bates J, Battiston R, Bazo J, Becker R, Becker U, Behlmann M, Beischer B, Berdugo J, Berges P, Bertucci B, Bigongiari G, Biland A, Bindi V, Bizzaglia S, Boella G, de Boer W, Bollweg K, Bolmont J, Borgia B, Borsini S, Boschini MJ, Boudoul G, Bourquin M, Brun P, Buénerd M, Burger J, Burger W, Cadoux F, Cai XD, Capell M, Casadei D, Casaus J, Cascioli V, Castellini G, Cernuda I, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen CR, Chen H, Cheng GM, Chen HS, Cheng L, Chernoplyiokov N, Chikanian A, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Commichau V, Consolandi C, Contin A, Corti C, Costado Dios MT, Coste B, Crespo D, Cui Z, Dai M, Delgado C, Della Torre S, Demirkoz B, Dennett P, Derome L, Di Falco S, Diao XH, Diago A, Djambazov L, Díaz C, von Doetinchem P, Du WJ, Dubois JM, Duperay R, Duranti M, D'Urso D, Egorov A, Eline A, Eppling FJ, Eronen T, van Es J, Esser H, Falvard A, Fiandrini E, Fiasson A, Finch E, Fisher P, Flood K, Foglio R, Fohey M, Fopp S, Fouque N, Galaktionov Y, Gallilee M, Gallin-Martel L, Gallucci G, García B, García J, García-López R, García-Tabares L, Gargiulo C, Gast H, Gebauer I, Gentile S, Gervasi M, Gillard W, Giovacchini F, Girard L, Goglov P, Gong J, Goy-Henningsen C, Grandi D, Graziani M, Grechko A, Gross A, Guerri I, de la Guía C, Guo KH, Habiby M, Haino S, Hauler F, He ZH, Heil M, Heilig J, Hermel R, Hofer H, Huang ZC, Hungerford W, Incagli M, Ionica M, Jacholkowska A, Jang WY, Jinchi H, Jongmanns M, Journet L, Jungermann L, Karpinski W, Kim GN, Kim KS, Kirn T, Kossakowski R, Koulemzine A, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, Laudi E, Laurenti G, Lauritzen C, Lebedev A, Lee MW, Lee SC, Leluc C, León Vargas H, Lepareur V, Li JQ, Li Q, Li TX, Li W, Li ZH, Lipari P, Lin CH, Liu D, Liu H, Lomtadze T, Lu YS, Lucidi S, Lübelsmeyer K, Luo JZ, Lustermann W, Lv S, Madsen J, Majka R, Malinin A, Mañá C, Marín J, Martin T, Martínez G, Masciocchi F, Masi N, Maurin D, McInturff A, McIntyre P, Menchaca-Rocha A, Meng Q, Menichelli M, Mereu I, Millinger M, Mo DC, Molina M, Mott P, Mujunen A, Natale S, Nemeth P, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oh S, Oliva A, Palmonari F, Palomares C, Paniccia M, Papi A, Park WH, Pauluzzi M, Pauss F, Pauw A, Pedreschi E, Pensotti S, Pereira R, Perrin E, Pessina G, Pierschel G, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pochon J, Pohl M, Poireau V, Porter S, Pouxe J, Putze A, Quadrani L, Qi XN, Rancoita PG, Rapin D, Ren ZL, Ricol JS, Riihonen E, Rodríguez I, Roeser U, Rosier-Lees S, Rossi L, Rozhkov A, Rozza D, Sabellek A, Sagdeev R, Sandweiss J, Santos B, Saouter P, Sarchioni M, Schael S, Schinzel D, Schmanau M, Schwering G, Schulz von Dratzig A, Scolieri G, Seo ES, Shan BS, Shi JY, Shi YM, Siedenburg T, Siedling R, Son D, Spada F, Spinella F, Steuer M, Stiff K, Sun W, Sun WH, Sun XH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tassan-Viol J, Ting SC, Ting SM, Titus C, Tomassetti N, Toral F, Torsti J, Tsai JR, Tutt JC, Ulbricht J, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vargas Trevino M, Vaurynovich S, Vecchi M, Vergain M, Verlaat B, Vescovi C, Vialle JP, Viertel G, Volpini G, Wang D, Wang NH, Wang QL, Wang RS, Wang X, Wang ZX, Wallraff W, Weng ZL, Willenbrock M, Wlochal M, Wu H, Wu KY, Wu ZS, Xiao WJ, Xie S, Xiong RQ, Xin GM, Xu NS, Xu W, Yan Q, Yang J, Yang M, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang JG, Zhang Z, Zhang MM, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P, Zurbach C. First result from the Alpha Magnetic Spectrometer on the International Space Station: precision measurement of the positron fraction in primary cosmic rays of 0.5-350 GeV. Phys Rev Lett. 2013 Apr 05; 110(14):141102. PMID: 25166975.
      Citations: 13     Fields:    
    211. Burger JA. The CLL cell microenvironment. Adv Exp Med Biol. 2013; 792:25-45. PMID: 24014291.
      Citations: 10     Fields:    Translation:Humans
    212. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013 Feb 10; 31(5):584-91. PMID: 23270003.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    213. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013 Feb 28; 121(9):1501-9. PMID: 23264597.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    214. Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol. 2012 Nov; 24(6):643-9. PMID: 22960555.
      Citations: 34     Fields:    Translation:HumansCells
    215. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    216. Burger JA. BRAF mutation: supporting diversity in HCL. Blood. 2012 Apr 05; 119(14):3193-4. PMID: 22493212.
      Citations: 2     Fields:    
    217. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012 Apr; 13(71):287-97. PMID: 22541616.
      Citations: 58     Fields:    Translation:HumansAnimals
    218. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8. PMID: 22422826.
      Citations: 83     Fields:    Translation:HumansCellsCTClinical Trials
    219. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia. 2012 Aug; 26(8):1812-20. PMID: 22460735.
      Citations: 23     Fields:    Translation:HumansCells
    220. Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012 Mar; 7(1):26-33. PMID: 22105489.
      Citations: 21     Fields:    Translation:HumansCells
    221. Davids MS, Burger JA. Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol. 2012; 3(S1). PMID: 22844583.
      Citations: 25     
    222. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012 Feb 19; 14(3):276-86. PMID: 22344033.
      Citations: 158     Fields:    Translation:HumansAnimalsCells
    223. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul; 26(7):1576-83. PMID: 22362000.
      Citations: 63     Fields:    Translation:HumansCells
    224. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012 Mar; 21(3):341-53. PMID: 22283809.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    225. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    226. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9. PMID: 22180443.
      Citations: 293     Fields:    Translation:HumansAnimalsCells
    227. Burger JA. The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. Expert Opin Med Diagn. 2012 Jan; 6(1):49-57. PMID: 23480620.
      Citations: 1     Fields:    
    228. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012 Apr; 97(4):599-607. PMID: 22058222.
      Citations: 33     Fields:    Translation:HumansCells
    229. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95. PMID: 21969505.
      Citations: 43     Fields:    Translation:Humans
    230. Burger JA, Hoellenriegel J. Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia.. Oncotarget. 2011 Oct; 2(10):737-8. PMID: 22006556.
      Citations: 12     Fields:    Translation:Humans
    231. Burger JA. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma. 2012 Jan; 53(1):3-4. PMID: 21830996.
      Citations: 1     Fields:    Translation:HumansAnimals
    232. Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol. 2011 Nov; 21(5):308-12. PMID: 21945516.
      Citations: 26     Fields:    Translation:HumansCells
    233. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 06; 118(14):3818-23. PMID: 21821712.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    234. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3603-12. PMID: 21803855.
      Citations: 240     Fields:    Translation:HumansCellsCTClinical Trials
    235. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2062-8. PMID: 21750315.
      Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
    236. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec; 42(12):1989-2000. PMID: 21733558.
      Citations: 10     Fields:    Translation:HumansCells
    237. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98. PMID: 21725050.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    238. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2085-93. PMID: 21670470.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    239. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40. PMID: 21512135.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    240. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011 Apr; 11(4):621-30. PMID: 21504328.
      Citations: 41     Fields:    Translation:HumansAnimals
    241. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 2011 Oct 15; 117(20):4689-95. PMID: 21456010.
      Citations: 23     Fields:    Translation:HumansCells
    242. Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:94-8. PMID: 21438839.
      Citations: 7     Fields:    Translation:HumansCells
    243. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17; 117(11):3016-24. PMID: 21245487.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    244. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:96-103. PMID: 22160019.
      Citations: 79     Fields:    Translation:HumansCells
    245. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. PMID: 21115978.
      Citations: 59     Fields:    Translation:Humans
    246. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol. 2010 Dec; 20(6):424-30. PMID: 20883788.
      Citations: 40     Fields:    Translation:HumansAnimals
    247. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2010 Dec 10; 28(35):e732-4. PMID: 20823404.
      Citations: 3     Fields:    Translation:Humans
    248. Ponader S, Burger JA. Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction? Haematologica. 2010 Sep; 95(9):e5. PMID: 20807980.
      Citations: 1     Fields:    Translation:HumansCells
    249. Burger JA. Angiopoietin-2 in CLL. Blood. 2010 Jul 29; 116(4):508-9. PMID: 20671131.
      Citations:    Fields:    
    250. Quiroga MP, Burger JA. BCR-mediated decrease of CXCR4 and CD62L in CLL. Cancer Res. 2010 Jun 15; 70(12):5194; author reply 5195. PMID: 20501831.
      Citations: 4     Fields:    Translation:Humans
    251. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7. PMID: 20466853.
      Citations: 119     Fields:    Translation:HumansCTClinical Trials
    252. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91. PMID: 20442367.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    253. Frank G, Kleinjung T, Landgrebe M, Vielsmeier V, Steffenhagen C, Burger J, Frank E, Vollberg G, Hajak G, Langguth B. Left temporal low-frequency rTMS for the treatment of tinnitus: clinical predictors of treatment outcome--a retrospective study. Eur J Neurol. 2010 Jul; 17(7):951-6. PMID: 20158510.
      Citations: 15     Fields:    Translation:Humans
    254. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia. 2010 Mar; 24(3):666-8. PMID: 20054352.
      Citations:    Fields:    Translation:HumansCells
    255. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009 Dec 15; 15(24):7456-7461. PMID: 19996200.
      Citations: 9     Fields:    
    256. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb; 148(3):386-93. PMID: 19895616.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    257. Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009 Sep 17; 114(12):2560-1; author reply 2561-2. PMID: 19762501.
      Citations: 9     Fields:    Translation:Humans
    258. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. PMID: 19762485.
      Citations: 147     Fields:    Translation:HumansAnimalsCells
    259. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18. PMID: 19517462.
      Citations: 37     Fields:    Translation:Humans
    260. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009 Oct 15; 114(16):3367-75. PMID: 19636060.
      Citations: 200     Fields:    Translation:HumansAnimalsCells
    261. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 03; 114(10):2037-43. PMID: 19567878.
      Citations: 37     Fields:    Translation:HumansCells
    262. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37. PMID: 19491390.
      Citations: 102     Fields:    Translation:HumansAnimalsCells
    263. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs. 2009 Apr; 18(4):481-90. PMID: 19335276.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    264. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009 May 28; 113(22):5549-57. PMID: 19318683.
      Citations: 58     Fields:    Translation:HumansCells
    265. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009 May 07; 113(19):4604-13. PMID: 19228923.
      Citations: 72     Fields:    Translation:HumansCells
    266. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43. PMID: 19224852.
      Citations: 28     Fields:    Translation:Humans
    267. Burger JA. CXCR4 in acute myelogenous leukemia (AML): when too much attraction is bad for you. Leuk Res. 2009 Jun; 33(6):747-8. PMID: 19091405.
      Citations: 3     Fields:    Translation:Humans
    268. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009 Mar 26; 113(13):3050-8. PMID: 19074730.
      Citations: 142     Fields:    Translation:HumansCells
    269. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009 Jan; 23(1):43-52. PMID: 18987663.
      Citations: 180     Fields:    Translation:HumansAnimals
    270. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53. PMID: 18836097.
      Citations: 67     Fields:    Translation:HumansCells
    271. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2008 Dec 15; 112(13):4839-42. PMID: 18818391.
      Citations: 23     Fields:    Translation:Humans
    272. Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica. 2008 Nov; 93(11):1728-33. PMID: 18790797.
      Citations: 8     Fields:    Translation:HumansCells
    273. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008 Mar; 92(3):351-5. PMID: 18211925.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    274. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3316-25. PMID: 17652619.
      Citations: 85     Fields:    Translation:HumansCells
    275. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007 May; 137(4):288-96. PMID: 17456052.
      Citations: 50     Fields:    Translation:Humans
    276. Burger JA. No cell is an island unto itself: the stromal microenvironment in chronic lymphocytic leukemia. Leuk Res. 2007 Jul; 31(7):887-8. PMID: 17234265.
      Citations: 4     Fields:    Translation:HumansCells
    277. Burger JA, Schmitt-Gräff A, Bürkle A, Seiler L, Finke J. Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. Leuk Lymphoma. 2006 Nov; 47(11):2427-30. PMID: 17107924.
      Citations: 1     Fields:    Translation:Humans
    278. Bossaller L, Burger J, Draeger R, Grimbacher B, Knoth R, Plebani A, Durandy A, Baumann U, Schlesier M, Welcher AA, Peter HH, Warnatz K. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol. 2006 Oct 01; 177(7):4927-32. PMID: 16982935.
      Citations: 182     Fields:    Translation:HumansAnimalsCells
    279. Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007 Jan 15; 109(2):786-91. PMID: 16888090.
      Citations: 122     Fields:    Translation:Humans
    280. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7. PMID: 16269611.
      Citations: 430     Fields:    Translation:HumansAnimalsCells
    281. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 2005 Jun 23; 24(27):4462-71. PMID: 15806155.
      Citations: 102     Fields:    Translation:HumansCells
    282. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30. PMID: 15905192.
      Citations: 100     Fields:    Translation:HumansCells
    283. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene. 2005 Mar 17; 24(12):2067-75. PMID: 15688008.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    284. Zeiser R, Mikesch K, Fisch P, Schaefer HE, Burger JA. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol. 2004 Jun; 125(6):679. PMID: 15180856.
      Citations:    Fields:    Translation:HumansCells
    285. Hartmann TN, Burger M, Burger JA. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. J Biol Regul Homeost Agents. 2004 Apr-Jun; 18(2):126-30. PMID: 15471215.
      Citations: 14     Fields:    Translation:HumansCells
    286. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Mönting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br J Haematol. 2004 Mar; 124(6):762-8. PMID: 15009064.
      Citations: 10     Fields:    Translation:Humans
    287. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101. PMID: 14603250.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    288. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol. 2003 Aug; 122(4):579-89. PMID: 12899713.
      Citations: 29     Fields:    Translation:HumansCells
    289. Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A, Burger J, Mingrone W, Herrmann R, Gratwohl A, Wernli M. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant. 2003 Jan; 31(2):99-103. PMID: 12621490.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    290. Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol. 2002 Aug; 29(4 Suppl 13):19-22. PMID: 12170428.
      Citations: 8     Fields:    Translation:HumansCells
    291. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstädt H. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol. 2002 Jun 15; 168(12):6244-52. PMID: 12055238.
      Citations: 38     Fields:    Translation:HumansCells
    292. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6. PMID: 12002747.
      Citations: 50     Fields:    Translation:HumansCells
    293. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7. PMID: 11807009.
      Citations: 84     Fields:    Translation:HumansCells
    294. Burger J. Landfills, nocturnal foraging, and risk to aircraft. J Toxicol Environ Health A. 2001 Oct 12; 64(3):273-90. PMID: 11594704.
      Citations: 3     Fields:    Translation:AnimalsPHPublic Health
    295. Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol. 2001 Sep; 108(3):417-23. PMID: 11544462.
      Citations: 9     Fields:    Translation:HumansCells
    296. Burger J, Gaines KF, Peles JD, Stephens WL, Boring CS, Brisbin IL, Snodgrass J, Bryan AL, Smith MH, Gochfeld M. Radiocesium in fish from the Savannah River and Steel Creek: potential food chain exposure to the public. Risk Anal. 2001 Jun; 21(3):545-59. PMID: 11572432.
      Citations: 8     Fields:    Translation:HumansAnimalsPHPublic Health
    297. Burger J, Snodgrass J. Metal levels in southern leopard frogs from the Savannah River Site: location and body compartment effects. Environ Res. 2001 Jun; 86(2):157-66. PMID: 11437462.
      Citations: 6     Fields:    Translation:AnimalsPHPublic Health
    298. Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine. 2001 Feb 28; 19(15-16):2181-9. PMID: 11228391.
      Citations: 7     Fields:    Translation:AnimalsCells
    299. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest. 2001 Feb; 107(3):305-15. PMID: 11160154.
      Citations: 49     Fields:    Translation:HumansCells
    300. Burger J, Gochfeld M. On developing bioindicators for human and ecological health. Environ Monit Assess. 2001 Jan; 66(1):23-46. PMID: 11214446.
      Citations: 15     Fields:    Translation:HumansAnimalsPHPublic Health
    301. Burger J. Integrating environmental restoration and ecological restoration: long-term stewardship at the department of energy. Environ Manage. 2000 Nov; 26(5):469-78. PMID: 10982725.
      Citations: 9     Fields:    
    302. Burger J. Recreation and risk around Los Alamos: are Hispanics more at risk? J Toxicol Environ Health A. 2000 Oct 27; 61(4):265-80. PMID: 11071320.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    303. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000 Oct 15; 96(8):2655-63. PMID: 11023495.
      Citations: 269     Fields:    Translation:HumansCells
    304. Burger J. Contaminated Department of Energy facilities and ecosystems: weighing the ecological risks. J Toxicol Environ Health A. 2000 Sep 29; 61(2):141-54. PMID: 11032427.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    305. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, Maini RN. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000; 2(6):477-88. PMID: 11056678.
      Citations: 178     Fields:    Translation:HumansCells
    306. Burger J. Gender differences in meal patterns: role of self-caught fish and wild game in meat and fish diets. Environ Res. 2000 Jun; 83(2):140-9. PMID: 10856187.
      Citations: 5     Fields:    Translation:HumansAnimalsPHPublic Health
    307. Burger J, Lord CG, Yurkow EJ, McGrath L, Gaines KF, Brisbin IL, Gochfeld M. Metals and metallothionein in the liver of raccoons: utility for environmental assessment and monitoring. J Toxicol Environ Health A. 2000 Jun; 60(4):243-61. PMID: 10914690.
      Citations: 6     Fields:    Translation:AnimalsPHPublic Health
    308. Burger J, Gochfeld M, Rooney AA, Orlando EF, Woodward AR, Guillette LJ. Metals and metalloids in tissues of American alligators in three Florida lakes. Arch Environ Contam Toxicol. 2000 May; 38(4):501-8. PMID: 10787102.
      Citations: 7     Fields:    Translation:Animals
    309. Burger J, Gochfeld M. Effects of lead on birds (Laridae): a review of laboratory and field studies. J Toxicol Environ Health B Crit Rev. 2000 Apr-Jun; 3(2):59-78. PMID: 10834076.
      Citations: 29     Fields:    Translation:AnimalsPHPublic Health
    310. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000 Mar; 108(3):641-52. PMID: 10759724.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    311. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999 Dec 01; 94(11):3658-67. PMID: 10572077.
      Citations: 170     Fields:    Translation:HumansCells
    312. Burger J, Sanchez J, McMahon M, Leonard J, Lord CG, Ramos R, Gochfeld M. Resources and estuarine health: perceptions of elected officials and recreational fishers. J Toxicol Environ Health A. 1999 Oct 29; 58(4):245-60. PMID: 10591491.
      Citations: 1     Fields:    Translation:HumansAnimalsPHPublic Health
    313. Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol. 1999 Aug 15; 163(4):2017-22. PMID: 10438939.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    314. Burger J, Sanchez J. Perceptions of on-site hunters: environmental concerns, future land use, and cleanup options at the Savannah river site. J Toxicol Environ Health A. 1999 Jun 25; 57(4):267-81. PMID: 10406350.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    315. Burger J, Stephens WL, Boring CS, Kuklinski M, Gibbons JW, Gochfeld M. Factors in exposure assessment: ethnic and socioeconomic differences in fishing and consumption of fish caught along the Savannah River. Risk Anal. 1999 Jun; 19(3):427-38. PMID: 10765415.
      Citations: 20     Fields:    Translation:HumansAnimalsPHPublic Health
    316. Burger J. American Indians, hunting and fishing rates, risk, and the Idaho National Engineering and Environmental Laboratory. Environ Res. 1999 May; 80(4):317-29. PMID: 10330305.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    317. Burger J. Recreation, consumption of wild game, risk, and the Department of Energy sites: perceptions of people attending the Lewiston, ID, "Roundup". J Toxicol Environ Health A. 1999 Feb 26; 56(4):221-34. PMID: 10706241.
      Citations:    Fields:    Translation:HumansAnimalsPHPublic Health
    318. Burger J, Sanchez J, Gochfeld M. Fishing, consumption, and risk perception in fisherfolk along an east coast estuary. Environ Res. 1998 Apr; 77(1):25-35. PMID: 9593625.
      Citations: 2     Fields:    Translation:HumansAnimalsPHPublic Health
    319. Burger J. Environmental attitudes and perceptions of future land use at the Savannah River Site: are there racial differences? J Toxicol Environ Health A. 1998 Feb 20; 53(4):255-62. PMID: 9490324.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    320. Burger J. Gender differences in attitudes about fish safety in a coastal population. J Toxicol Environ Health A. 1998 Feb 06; 53(3):181-92. PMID: 9482350.
      Citations: 2     Fields:    Translation:HumansAnimalsPHPublic Health
    321. Sach M, Burger JA, Engelhardt A, Ketelsen UP, Schollmeyer P. [Temporary hemiparesis and Raynaud symptoms in eosinophilic fasciitis]. Internist (Berl). 1997 Jul; 38(7):688-91. PMID: 9333603.
      Citations:    Fields:    Translation:Humans
    322. Sach M, Bauermeister K, Burger JA, Loetscher P, Elsner J, Schollmeyer P, Dobos GJ. Inverse MCP-1/IL-8 ratio in effluents of CAPD patients with peritonitis and in isolated cultured human peritoneal macrophages. Nephrol Dial Transplant. 1997 Feb; 12(2):315-20. PMID: 9132652.
      Citations: 3     Fields:    Translation:HumansCells
    323. Burger JA, Ochs A, Wirth K, Berger DP, Mertelsmann R, Engelhardt R, Roessle M, Haag K. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol. 1997 Feb; 8(2):200-2. PMID: 9093733.
      Citations: 6     Fields:    Translation:Humans
    324. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia. 1997 Feb; 11(2):281-3. PMID: 9009093.
      Citations: 5     Fields:    Translation:HumansCells
    325. Burger JA, Schöffel U, Sach M, Jacobs E, Kownatzki E, von Specht BU, Farthmann EH. Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Eur J Surg. 1995 Sep; 161(9):647-53. PMID: 8541423.
      Citations:    Fields:    Translation:HumansCells
    326. Sach M, Loetscher P, Burger JA, Knopf HP, Schollmeyer P, Dobos GJ. MCP-1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages. Adv Perit Dial. 1995; 11:19-23. PMID: 8534702.
      Citations: 1     Fields:    Translation:HumansCells
    327. Michal M, Baumruk L, Burger J, Manhalová M. Adenomyoepithelioma of the breast with undifferentiated carcinoma component. Histopathology. 1994 Mar; 24(3):274-6. PMID: 7515373.
      Citations: 12     Fields:    Translation:Humans
    328. Caspar CB, Seger RA, Burger J, Gmür J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood. 1993 Jun 01; 81(11):2866-71. PMID: 7684619.
      Citations: 12     Fields:    Translation:HumansCells
    329. Guo Z, Wang M, Tian G, Burger J, Gochfeld M, Yang CS. Age- and gender-related variations in the activities of drug-metabolizing and antioxidant enzymes in the white-footed mouse (Peromyscus leucopus). Growth Dev Aging. 1993; 57(2):85-100. PMID: 8495997.
      Citations: 7     Fields:    Translation:HumansAnimals
    330. Burger J, Gmür J, Bruckner-Tuderman L. Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation? Bone Marrow Transplant. 1992 Feb; 9(2):139-41. PMID: 1571712.
      Citations: 4     Fields:    Translation:Humans
    331. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991 Nov 16; 338(8777):1223-6. PMID: 1682642.
      Citations: 23     Fields:    Translation:Humans
    332. Gmür JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D, Metaxas M. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood. 1990 Jan 01; 75(1):290-5. PMID: 2294993.
      Citations: 19     Fields:    Translation:Humans
    333. Stahel RA, Jost LM, Burger J, Honegger HP, Brun del Re GP, Gmür J. [High-dosage chemo-radiotherapy with autologous bone marrow transfusion in malignant lymphoma: indications and personal experience]. Schweiz Med Wochenschr. 1989 Jun 24; 119(25):911-7. PMID: 2667131.
      Citations:    Fields:    Translation:Humans
    334. Gmür J, Burger J, Frick P. [Low early mortality after allogeneic bone marrow transplantation thanks to rigorous sterility measures, modified whole body irradiation, cyclosporin A and antiviral precautions]. Schweiz Med Wochenschr. 1985 Oct 26; 115(43):1524-5. PMID: 3001930.
      Citations:    Fields:    Translation:HumansPHPublic Health
    335. Cutie A, Burger J, Clawans C, Dolinsky D, Feinstein W, Gupta B, Grueneberg A, Sciarra J. Test for reproducibility of metered-dose aerosol valves for pharmaceutical solutions. J Pharm Sci. 1981 Sep; 70(9):1085-7. PMID: 6101162.
      Citations:    Fields:    
    336. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia.
    337. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    338. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7.
    339. Targeting CXCR4 in chronic lymphocytic leukemia. 369-385.
    340. PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Current Topics in Microbiology and Immunology. 393:123-142.
    341. Cell trafficking in chronic lymphocytic leukemia. Open Hematology Journal. 3.
    342. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies. Clinical Advances in Hematology and Oncology. 14:55-65.
    343. Fledgling prognostic markers in CLL. Blood. 110:3820-3821.
    344. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.
    345. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 30:325-330.
    346. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    347. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia. Biochimica et Biophysica Acta - Molecular Cell Research.
    348. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. British Journal of Haematology.
    349. The microenvironment in chronic lymphocytic leukemia. 56-71.
    350. Ibrutinib Is effective in relapsed CLL. Cancer Discovery. 3.
    351. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    352. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.
    353. The CLL cell microenvironment. 25-45.
    354. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    355. Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research. 22:2359-2367.
    356. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer.
    357. The importance of the tissue microenvironment in hairy cell leukemia. Best Practice and Research: Clinical Haematology. 28:208-216.
    358. Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia. Journal of Immunology. 197:2522-2531.
    359. Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell. 27:409-425.
    360. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology. 92:7-11.
    361. Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.
    362. Chronic lymphocytic leukemia therapy. Expert Opinion on Pharmacotherapy. 1-13.
    363. β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 122:565-573.
    364. Hematological neoplasia. 400-526.
    365. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. The Lancet Oncology. 15:48-58.
    366. Haematologica. 101:e295-e298.
    367. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 126:2686-2694.
    368. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 101:e254-e258.
    369. Nurse-like cells that support leukemic B cell survival are highly effective antigen presenting cells. Blood. 96.
    370. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia.
    371. Bendamustine in B-cell malignancies. Clinical Cancer Research. 15:7456-7461.
    372. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. British Journal of Haematology.
    373. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    374. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia.
    375. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.
    376. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma.
    377. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    378. Obinutuzumab. Blood. 127:6-8.
    379. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. British Journal of Haematology. 171:281-284.
    380. Special diagnostics. 39-64.
    381. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplantation. 52:28-33.
    382. Nurse-like cells that support survival of chronic lymphocytic leukemia cells are derived from blood monocytes. Blood. 96.
    383. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.
    384. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 7:65968-65981.
    385. The bone marrow microenvironment and its impact in acute and chronic B cell malignancies. 35-45.
    BURGER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (875)
    Explore
    _
    Co-Authors (95)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _